Introduction: Device-associated healthcare-associated infections (DA-HAIs) are the principal threat to patient safety in intensive care units (ICUs). The primary objective of this study was to identify the most common DA-HAIs in the pediatric intensive care unit (PICU) at the American University of Beirut Medical Center (AUBMC). Length of stay (LOS) and mortality, antimicrobial resistance patterns, and suitability of empiric antibiotic choices for DA-HAIs according to the local resistance patterns were also studied. Methodology: This was a retrospective study that included all patients admitted to the PICU at AUBMC between January 2007 and December 2011. All patients admitted to the PICU having a placed central line, an endotracheal tube, and/or a Foley catheter were included. Data was extracted from the patients' medical records through chart review. A total of 22 patients were identified with 25 central line-associated bloodstream infections (CLABSI), 25 ventilator-associated pneumonia (VAP), and 9 catheter-associated urinary tract infections (CAUTIs). The causing organisms, their resistance patterns, and the appropriateness of empiric antimicrobial therapy were reported. Results: Gram-negative pathogens were found in 53% of the DA-HAIs, Gram-positive ones in 27%, and fungal organisms in 20%. A total of 80% of K. pneumonia isolates were extended-spectrum beta-lactamases (ESBL) producers, and 30% of Pseudomonas isolates were multidrug resistant. No methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococci (VRE) were isolated. Based on culture results, the choice of empiric antimicrobial therapy was appropriate in 64% of the DA-HAIs. Conclusions: After the care bundle approach is adopted in our PICU, DA-HAIs are expected to decrease further.
Introduction
Healthcare-acquired infections (HAIs) are a major cause of morbidity and mortality, prolonged hospital stays, and greater healthcare costs worldwide. The extensive use of invasive devices in patients in intensive care units (ICUs) puts them at a particularly increased risk of infection. The leading causes of death in noncardiac intensive care units (ICUs) are infections and sepsis [1] . In most hospitals, the ICU-acquired infections account for more than 20% of all nosocomial infections [2] . The point prevalence for pediatric intensive care unit (PICU)-acquired infections in the United States ranges around 12%-15% among patients in PICUs [3] .
Device-associated healthcare-associated infections (DA-HAI) are the principal threat to patient safety in the ICUs, complicating patient care in both low-and high-income countries [4] . The implications include prolonged hospital stay, long-term disability, increased resistance of microorganisms to antibiotics, massive additional financial burden for healthcare systems, high costs for patients and their families, and unnecessary deaths. In medical and surgical PICUs in the US, the rate of central line-associated bloodstream infections (CLABSIs) is 1.43 per 1,000 central line-days [5] . The rate of urinary catheter-associated urinary tract infections (CAUTIs) is 2.71 per 1,000 urinary catheterdays and that of ventilator-associated pneumonia (VAP) is 0.77 per 1,000 ventilator-days [5] .
The World Health Organization (WHO) assessed the rates of DA-HAIs in the ICUs of low-and middleincome countries in a systematic review [4] . The rate of CLABSI was 12.2 per 1,000 central line-days, CAUTI was 12.2 per 1,000 urinary catheter-days, and VAP was 23.9 per 1,000 ventilator-days. Another study from the Philippines investigated the rates of DA-HAI in nine adult, pediatric, and neonatal ICUs of three hospital members of the International Nosocomial Infection Control Consortium (INICC) and found that the rate of CLABSI was 4.6 per 1,000 central line-days, CAUTI was 4.2 per 1,000 urinary catheter-days, and VAP was 16.7 per 1,000 ventilator-days [6] .
Since 1985, the Centers for Disease Control and Prevention (CDC) has established the efficacy of infection surveillance and control programs in reducing nosocomial infections in the United States [7] . Implementation of such programs reduced nosocomial infections by 32%. The DA-HAI surveillance played an important role in reducing the rates of HAIs and improving hospital infection control and quality assurance in developed countries [8, 9] . National surveillance systems for HAIs exist in several highincome countries but are virtually nonexistent in most low-and middle-income countries.
In a study of PICUs from 16 countries with limited resources, the INICC found that lower-middle-income countries had higher rates of CLABSI, VAP, and CAUTI than did upper middle-income countries: 12.2 vs. 7.0 per 1,000 central line-days, 9.0 vs. 5.4 per 1,000 ventilator-days, and 5.9 vs. 3.7 per 1,000 urinary catheter-days, respectively [10] . In a Thai PICU, the rate of HAIs was 28.3 per 1,000 patient-days [11] . In a Brazilian PICU, the rate of VAPs was 27.1 per 1,000 ventilator-days [12] . In a Peruvian PICU, the rates of BSIs, VAPs and UTIs were 18.1 per 1,000 central venous catheter (CVC)-days, 7.9 per 1,000 endotracheal tube (ETT)-days, and 5.1 per 1,000 urinary catheter-days respectively [13] . The findings of the INICC in Egypt from two PICUs were 22.8 DAHAIs per 1,000 ICU-days, 18.8 CLABSIs per 1,000 line-days, and 31.8 VAPs per 1,000 ventilator-days [14] . In a Tunisian PICU, the rate of CVC-associated infections was 14.8 per 1,000 catheter-days [15] .
Very few studies describe the pattern of DA-HAIs in PICUs in the Middle East region, or in Lebanon specifically. The aim of this study was to identify the most common types of DA-HAIs in the PICU at the American University of Beirut Medical Center (AUBMC). Secondary aims included assessing the length of stay (LOS) and mortality, as well as studying the antimicrobial resistance pattern and the adequacy of empiric antibiotic choices for DA-HAIs according to the local resistance patterns. We also discuss the benefits of the adopted Institute for Healthcare Improvement bundles of interventions that are aimed at minimizing DA-HAIs.
Methodology

Setting and study design
AUBMC is a tertiary-care center in Beirut and a major referral center for Lebanon and its neighboring countries. The pediatric ICU consists of an eight-bed closed unit that admits surgical and medical pediatric and adolescent patients (up to 21 years of age) and accepts referral from other hospitals. A team of house staff officers runs the unit under the supervision of a pediatric intensivist. The nurse-to-patient ratio during the study period was 1:1-2. The Infection Control and Prevention Program (ICPP) collects data on all DA-HAI in all the closed units, including the PICUs. Data is obtained from the microbiology laboratory, the radiology department, and by reviewing patients' charts on a daily basis. The adult ICUs at AUBMC have been members of the INICC for many years. The approval of an infectious diseases specialist is required for the use of broad-spectrum antimicrobial agents.
This was a retrospective study that included all patients admitted to the PICU at AUBMC between January 2007 and December 2011. Data was extracted from the patients' medical records. Inclusion criteria included having at least one of a placed central line, endotracheal tube, or Foley catheter. Among all patients admitted to the PICU during the time period of the study, the ICPP identified 31 patients as having DAHAIs. A total of 5 patients were excluded from the study because they had a missing chart or a large portion of unavailable data. Chart review was done for 26 patients only, 4 of whom were excluded later for not meeting the set definitions of CLABSI, VAP, and/or CAUTI at any point during their stay in the PICU. The discrepancy in the number of DA-HAIs in this study compared with ICPP regarding the 4 excluded patients was due to the fact that the infection developed during their hospital stay but not during their stay in the PICU.
The institutional review board at AUBMC approved this study protocol.
Definitions of DA-HAIs
When an infection met the criteria of a DA-HAI in areas of the hospital other than the PICU and the patient was later transferred to the PICU, the infection was not considered in this analysis. The definitions of CLABSI, VAP, and CAUTI were adapted from those of the CDC [16] [17] [18] . CLABSI is a primary bloodstream infection that is attributed to the use of a central line. VAP is a pneumonia related to ventilator placement, and CAUTI is a UTI related to placement of an indwelling catheter. The first CDC criterion for any of the three infections is that they must have occurred at least on the second day of placement of the respective device. Second, if the device was removed after two days of placement or more, an infection occurring, at most, on the day following the removal of the device was also considered to be associated with the respective device.
Microbiological testing
The standard practice at the PICU for patients with clinical suspicion of infection in the presence of a device is to obtain specimens for microbiology analysis. Qualitative cultures were performed on peripheral or central blood, deep tracheal aspirate, or sputum, and quantitative cultures were done on sterile urine samples. Standard methods were used for identification of microorganisms. Antimicrobial susceptibility testing was performed on isolates and determined by the diskdiffusion method based on the report from the Clinical and Laboratory Standards Institute on interpretation and quality control aspects published each year [19] .
Length of stay and mortality calculations
The hospital LOS was calculated as the total number of days from admission to the hospital to discharge from the hospital or death. The PICU LOS was calculated as the total number of days spent in the PICU, even if intermittently, during the hospital admission. Due to the debatable cutoff values in the literature, the adopted definition of prolonged PICU stay was, by convention, more than 14 days in the PICU. The crude mortality rate was calculated as the percentage of deaths among the total number of patient with DA-HAIs in the PICU. Excess LOS and excess mortality were not derivable with the data available.
Antimicrobial coverage
Effective antimicrobial coverage for a DA-HAI was defined as initiation of an empiric antimicrobial agent to which the bacteria turned out to be sensitive. Empiric therapy was defined as the initiation of treatment soon after the culture specimen was obtained but before the physician in charge was informed of a positive culture result, which included the result of a Gram stain.
Statistical analysis
Microsoft Excel was used for data entry and management. The Statistical Package for Social Sciences (SPSS, Chicago, USA) program, version 20.0 for Windows, was used for data analysis. The descriptive statistics reported for continuous variables included the mean and standard deviation (SD) for the overall sample. For subgroups, only the median was reported because of the distribution of small numbers of patients. No tests of comparison were conducted.
Results
Characteristics of the study population
The study population comprised all patients with DA-HAIs over the span of 5 years (n = 22), 10 of whom (45.5%) were females, 6 were (27.3%) immunocompromised, and 16 (72.7%) had a prolonged hospital stay. The detailed individual characteristics of the patients are listed in Table 1 . The patients' ages ranged between 3 days and 20 years, with a median of 16.8 months and a mean of 5.0 ± 6.7 years (mean ± SD). The overall median (and mean ± SD) for the hospital LOS and PICU LOS were, respectively, 54 (74 ± 70) and 32 (44 ± 46) days. The LOS distributions were skewed to the right -i.e., the medians were smaller than the means -because two chronic patients stayed in the PICU for 131 and 207 days. In total, 17 patients had more than one DA-HAI. The total number of DA-HAIs was 59, distributed among the 22 patients as follows: 25 CLABSIs in 15 patients, 25 VAPs in 16 patients, and 9 CAUTIs in 7 patients. Mortality was observed in 8 patients (36.4%) out of 22 (Table 1) . Tables 2 and 3 show the LOS and crude mortality for the different types of DA-HAIs.
Microorganism profile, bacterial resistance, and antimicrobial coverage
Gram-negative pathogens were found in 53% of the DA-HAIs, Gram-positive ones in 27%, and fungal organisms in 20%.
DA-HAIs were caused by coagulase-negative staphylococci (22.0%), Candida species (18.7%), Klebsiella species (16.9%), Pseudomonas species (11.9%), Escherichia coli (10.2%), and Enterobacter species (6.8%). Staphylococcus aureus and Acinetobacter species were isolated in two DA-HAIs each. Serratia marcescens, Stenotrophomonas maltophila, Enterococcus species, and Trichosporon asahii were isolated in one DA-HAI each (Table 4) .
All Klebsiella species isolates were resistant to ampicillin, but sensitive to imipenem and cefoxitin. A total of 80% of K. pneumonia isolates were extendedspectrum beta-lactamase (ESBL) producers. In four of the cases, empiric antimicrobial therapy was appropriate. One of the two remaining sensitive K. pneumoniae DAHAIs was covered with appropriate antibiotics. For the isolated Pseudomonas species, 28.6% were resistant to amikacin, ceftazidime, cefepime, ciprofloxacin, gentamicin, piperacillin/tazobactam, and tobramycin, while 42.9% were resistant to aztreonam and imipenem. Of six P. aeruginosa isolates, two were multidrug resistant (MDR), defined as resistant to β-lactams, carbapenems, aminoglycosides, and fluoroquinolones, and were not effectively covered empirically. Of the four sensitive isolates, only one was not effectively covered because no antimicrobial with pseudomonal coverage was given.
All of the six E. coli isolates were effectively covered with empiric antibiotics. Although four of them were ESBL producers, of the two isolates of Acinetobacter species, the A. anitratus isolate was sensitive and covered empirically effectively, while the A. baumannii isolate was MDR and empiric antibiotic coverage was ineffective. The two S. aureus isolates were methicillin sensitive and effectively covered empirically. There were no methicillin-resistant Staphylococcus aureus (MRSA) or vancomycinresistant enterococci (VRE) isolated in any of the DAHAIs in the PICU, although MRSA has been encountered in other units at AUBMC [20] .
Overall, of the DA-HAIs of bacterial nature, around two-thirds -61.3% of Gram-negative and 68.8% of Gram-positive isolates -were effectively covered with empiric therapy (Table 5 ). When aminoglycosides, carbapenems, and glycopeptides were used for empiric therapy, they were effective around three-quarters Example: Of the 12 prescriptions of aminoglycosides, 75% correctly covered the corresponding device-associated healthcare-associated infections (DA-HAI). (70%-76.5%) of the time (Table 6 ). The combination of piperacillin/tazobactam was used for one DA-HAI, and it was an effective empiric treatment. The same applied for amoxicillin/clavulanate. In 27.3% of the DA-HAIs where cephalosporins were used, there was shortage on covering the DA-HAI-causing bacteria. In all the cases where a fluoroquinolone was used, there was failure in efficacious empiric therapy. Table 5 shows the details of effective empiric coverage of CLABSIs, VAPs, and CAUTIs separately. Detailed descriptions of DA-HAIs, recovered organisms, resistance, and effective coverage in empiric therapy for CLABSIs, VAPs, and CAUTIs are shown in Tables 7a, 7b , and 7c, respectively.
Discussion
HAIs [22] . In our study, VAP was the most common type of DA-HAI (25 new occurrences in 16 patients), followed by CLABSI (25 new occurrences in 15 patients) and CAUTI (9 new occurrences in 7 patients). These results are similar to those found in other developing countries, where VAP is the most common cause of DAIs, as compared to the high-income countries, where CAUTI is the most common type [4] . Benson et al. reported prevention of VAP over 33 consecutive months using a VAP bundle protocol along with the use of a polyurethane endotracheal tube, in addition to comprehensive education and the cooperation between physicians, nurses, and respiratory therapists [23] . Aligning with Benson et al.'s recommendations, more efforts directed toward monitoring of compliance to bundle elements should take place in the PICU at AUBMC to further decrease the rates of VAP and CLABSI.
Coagulase-negative Staphylococcus (9 CLABSI and 4 VAP) was the most common cause of DA-HAIs, followed by Klebsiella species (3 CLABSI, 4 VAP, and 3 CAUTI). This was different from the nosocomial infections among PICU patients in Alexandria, Egypt [24] , where Klebsiella species were the most commonly isolated pathogens (46.7%), followed by Pseudomonas aeruginosa (16.6%). Another study in the Arab region of Tunis [15] showed Staphylococcus aureus to be the most common cause (26.8%) of nosocomial bloodstream infections, followed by Klebsiella pneumoniae (19.5%) and coagulase-negative staphylococci (17%). A study from Shanghai, China showed Acinetobacter baumannii (19.1%), followed by Pseudomonas aeruginosa (17.2%), Klebsiella pneumoniae (11.9%), and Staphylococcus aureus (11.9%) to be the most commonly isolated microorganisms in patients with DA-HAIs [25] .
Empiric antimicrobial therapy in our patients was effectively initiated in most cases (65%) before knowledge of the final culture results and antimicrobial susceptibility. In our study, Klebsiella and E. coli species were ESBL producing in 80% and 67% of isolates, respectively. Pseudomonas species were multidrug resistant in 34% of the cases. In the Tunisian study, Klebsiella species produced ESBLs in 87.5% of cases [15] .
Conclusions
One major limitation of this study was the small number of patients with DA-HAIs. However, such a small number indirectly indicates a low rate of DAHAIs in the PICU at AUBMC. Still, we were not able to calculate the rates of CLABSI, CAUTI, and VAP per 1,000 device-days because the total device-day numbers were not available. Also, because of the low numbers, we could not generalize about the adequacy of antibiotic coverage. Subsequently, subset analysis by source of device (location of placement) and time-toevent survival analysis were both not possible for the same reason. These would better be derived from prospective studies with a larger number of patients. The second major limitation in our study was the unavailability of data on the total numbers of devices placed in patients admitted to the PICU. We are currently in the process of a prospective collection of data in order to document the most recent trend in DAHAIs in AUBMC, especially after the implementation of bundles of care and hygiene.
